Profile data is unavailable for this security.
About the company
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).
- Revenue in USD (TTM)886.00k
- Net income in USD-338.79m
- Incorporated2013
- Employees30.00
- LocationSpyre Therapeutics Inc221 Crescent Street, Suite 105WALTHAM 02453United StatesUSA
- Phone+1 (617) 651-5940
- Fax+1 (302) 636-5454
- Websitehttps://spyre.com/
More ▼
Mergers & acquisitions
| Acquired company | SYRE:NSQ since announced | Transaction value |
|---|---|---|
| Spyre Therapeutics Inc | 1,161.65% | 1.42m |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | 186.37m | -163.42m | 1.15bn | 264.00 | -- | 4.60 | -- | 6.17 | -4.08 | -4.08 | 4.56 | 5.32 | 0.3729 | 3.37 | 4.05 | 705,962.10 | -32.70 | -38.93 | -38.55 | -44.88 | 74.76 | -- | -87.68 | -190.71 | 4.19 | -79.67 | 0.552 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.18bn | 20.00 | -- | 12.81 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 1.18bn | 355.00 | -- | 3.36 | -- | 7.25 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| 4D Molecular Therapeutics Inc | 20.72m | -100.84m | 1.19bn | 147.00 | -- | 3.25 | -- | 57.40 | -2.58 | -2.58 | 0.5438 | 7.15 | 0.0689 | -- | -- | 140,972.80 | -33.52 | -32.67 | -35.57 | -34.90 | -- | -- | -486.59 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.19bn | 197.00 | 41.28 | 5.94 | 6.03 | 2.10 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Tarsus Pharmaceuticals Inc | 17.45m | -135.89m | 1.20bn | 244.00 | -- | 5.56 | -- | 68.85 | -4.58 | -4.58 | 0.5939 | 5.76 | 0.0707 | -- | 1.64 | 71,504.10 | -55.09 | -31.56 | -61.63 | -33.82 | 90.87 | -- | -778.89 | -242.59 | 6.85 | -- | 0.1315 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Xencor Inc | 168.34m | -126.09m | 1.22bn | 280.00 | -- | 1.82 | -- | 7.25 | -2.10 | -2.10 | 2.79 | 10.96 | 0.1872 | -- | 8.36 | 601,207.10 | -14.04 | -3.70 | -15.30 | -4.12 | -- | -- | -75.00 | -15.92 | -- | -- | 0.0304 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.22bn | 267.00 | -- | -- | -- | 2.76 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Pacira Biosciences Inc | 674.98m | 41.96m | 1.22bn | 711.00 | 38.79 | 1.41 | 10.41 | 1.81 | 0.6789 | 0.6789 | 12.33 | 18.72 | 0.4147 | 1.84 | 6.62 | 949,336.10 | 2.58 | 3.35 | 2.79 | 3.98 | 72.64 | 72.63 | 6.22 | 8.57 | 4.17 | 9.85 | 0.3752 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Spyre Therapeutics Inc | 886.00k | -338.79m | 1.23bn | 30.00 | -- | -- | -- | 1,386.33 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Pharvaris NV | 0.00 | -107.86m | 1.26bn | 82.00 | -- | 2.97 | -- | -- | -2.70 | -2.70 | 0.00 | 7.85 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.26bn | 297.00 | 209.86 | 2.93 | 116.25 | 4.18 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Soleno Therapeutics Inc | 0.00 | -38.99m | 1.27bn | 33.00 | -- | 7.62 | -- | -- | -2.97 | -2.97 | 0.00 | 4.97 | 0.00 | -- | -- | 0.00 | -37.64 | -53.90 | -41.40 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Ligand Pharmaceuticals Inc | 131.31m | 53.82m | 1.27bn | 58.00 | 24.28 | 1.77 | 14.03 | 9.65 | 2.91 | 2.81 | 7.26 | 39.92 | 0.1695 | 0.5642 | 4.15 | 2,264,035.00 | 6.94 | 12.32 | 7.50 | 12.99 | 91.99 | 81.65 | 40.98 | 80.32 | 12.72 | -- | 0.00001 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -188.92m | 1.30bn | 155.00 | -- | 3.76 | -- | -- | -2.37 | -2.37 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.11 | -- | -55.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Spyre Therapeutics Inc's reporting currency: US Dollar USD
49.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.79m | 10.47% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 2.61m | 7.21% |
| RTW Investments LPas of 31 Dec 2023 | 2.23m | 6.18% |
| Deep Track Capital LPas of 31 Dec 2023 | 1.95m | 5.40% |
| Commodore Capital LPas of 31 Dec 2023 | 1.88m | 5.21% |
| Avoro Capital Advisor LLCas of 31 Dec 2023 | 1.84m | 5.09% |
| Adage Capital Management LPas of 31 Dec 2023 | 1.00m | 2.77% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 937.08k | 2.59% |
| EcoR1 Capital, LLCas of 31 Dec 2023 | 887.08k | 2.45% |
| Driehaus Capital Management LLCas of 31 Dec 2023 | 771.90k | 2.14% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
